Xilio Therapeutics Inc XLO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $9.20
- Day Range
- $9.08–9.20
- 52-Week Range
- $6.69–12.62
- Bid/Ask
- $0.00 / $0.00
- Shares Outstanding
- 6.58M
- Market Cap
- $59.83M
- Volume/Avg
- 18,964 / 45,889
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.55
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 76
- Website
- https://www.xiliotx.com
Valuation
|
Metric
|
XLO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.74 |
Price/Sales | 1.55 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
XLO
|
|---|---|
Quick Ratio | 3.50 |
Current Ratio | 3.59 |
Interest Coverage | — |
Quick Ratio
XLO
Profitability
|
Metric
|
XLO
|
|---|---|
Return on Assets (Normalized) | −23.81% |
Return on Equity (Normalized) | −139.71% |
Return on Invested Capital (Normalized) | −106.75% |
Return on Assets
XLO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|j<blFpP | LOCK|#M#w? | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|><Zy&B | LOCK|bm<? | $70B | |||
| argenx SE ADR
ARGX
| LOCK|gLY?dMz | LOCK|$^ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Pv@^dHk | LOCK|W&#! | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!Rd%b<x | LOCK|dL@ | $36B | |||
| Moderna Inc
MRNA
| LOCK|@@gJrFC | LOCK|Cf | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|lPjtsF%H | LOCK|g^d@ | $25B | |||
| Incyte Corp
INCY
| LOCK|rP!y>$ | LOCK|dR | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Kct&xq | LOCK|^c^ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|XSk$@C | LOCK|t^Q | $17B |
United States